Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Antimicrobial resistance

Antimicrobial resistance must be 'top five priority' for government, MPs say

A House of Commons report has urged the government to financially prioritise antimicrobial resistance research and development.

Amoxicillin blister pack


The parliamentary report notes that there has been little progress in developing new antibiotics for several decades

Tackling antimicrobial resistance (AMR) needs to be firmly established as a ‘top five policy priority’ for the government to help prevent the worldwide loss of modern medicine, according to a new report by the House of Commons Health and Social Care Select Committee.

The committee called for targeted prescribing, action to prevent infection, and the development of new antimicrobial treatments to help tackle the growing threat of AMR.

With UK prescribing levels still approximately double that of the Netherlands, Sweden and the Baltic states, the report noted that “a rapid review and withdrawal of clinically unnecessary secondary care prescribing is needed”.

The report highlighted that it has been several decades since a new class of antibiotics has been developed. The committee recommended government investment in basic scientific research, in addition to investment by pharmaceutical companies into further development and bringing antimicrobial products to market.

Sarah Wollaston, chair of the committee, said: “In six months, we want to see tangible progress on implementing practical policies to reverse the worrying exodus from AMR research and development, and both government and industry should play their part in tackling this issue.”

Digital health tools for clinicians and policymakers could dramatically help to reduce the threat of AMR but the committee found the variation in the uptake of best practice was unacceptable.

It advised: “A single organisation should be given responsibility for coordinating clinical decision support systems across the NHS, and ensuring they prompt evidence-based prescribing of antimicrobial [and] other medicines.”

The strategy should also include commitments to establish safe discharge levels for human waste, agricultural waste and pharmaceutical manufacturing waste, and to introduce systems to monitor and enforce them. 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2018.20205635

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Amoxicillin blister pack

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.